MindImmune Secures $5 Million Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Pioneer Immune-Driven Therapies for Alzheimer’s Disease
MindImmune today announced a transformative $5 million award from the Alzheimer’s Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 — a first-in-class program designed to target immune pathways driving neuroinflammation and neurodegeneration in Alzheimer’s disease.
